A detailed history of Charles Schwab Investment Management Inc transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 51,290 shares of VRCA stock, worth $407,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,290
Previous 51,290 -0.0%
Holding current value
$407,755
Previous $373,000 9.12%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$5.89 - $9.56 $23,948 - $38,870
-4,066 Reduced 7.35%
51,290 $373,000
Q2 2023

Aug 09, 2023

BUY
$5.32 - $6.79 $294,493 - $375,867
55,356 New
55,356 $319,000
Q3 2022

Nov 14, 2022

BUY
$2.17 - $4.3 $27,281 - $54,059
12,572 New
12,572 $37,000
Q2 2022

Aug 15, 2022

SELL
$1.81 - $8.93 $60,544 - $298,708
-33,450 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$9.55 - $13.96 $22,280 - $32,568
2,333 Added 7.5%
33,450 $419,000
Q1 2021

May 17, 2021

SELL
$10.51 - $17.46 $5,412 - $8,991
-515 Reduced 1.63%
31,117 $472,000
Q4 2020

Feb 16, 2021

BUY
$7.41 - $12.63 $1,244 - $2,121
168 Added 0.53%
31,632 $365,000
Q3 2020

Nov 13, 2020

SELL
$6.16 - $10.3 $14,303 - $23,916
-2,322 Reduced 6.87%
31,464 $244,000
Q1 2020

May 15, 2020

BUY
$7.14 - $16.86 $35,321 - $83,406
4,947 Added 17.15%
33,786 $370,000
Q4 2019

Feb 07, 2020

SELL
$13.08 - $17.43 $66,302 - $88,352
-5,069 Reduced 14.95%
28,839 $459,000
Q3 2019

Nov 08, 2019

BUY
$8.65 - $14.81 $61,371 - $105,076
7,095 Added 26.46%
33,908 $501,000
Q2 2019

Aug 09, 2019

BUY
$7.1 - $11.62 $5,183 - $8,482
730 Added 2.8%
26,813 $312,000
Q1 2019

May 14, 2019

BUY
$7.95 - $14.07 $120,148 - $212,639
15,113 Added 137.77%
26,083 $282,000
Q3 2018

Nov 13, 2018

BUY
$13.94 - $19.88 $152,921 - $218,083
10,970 New
10,970 $179,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.